18 results on '"Schönland S"'
Search Results
2. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT
3. Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse
4. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial
5. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
6. Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma
7. Genotype and phenotype heterogeneity of transthyretin-associated amyloidosis - A report from the German amyloidosis referral center: OS3223
8. ONE-YEAR SURVIVAL AFTER AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION CENTER IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS HAS STEADILY IMPROVED FROM 1997 TO 2010 IN EBMT CENTERS: WP-O016
9. The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison†
10. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation
11. Second allogeneic haematopoietic stem cell transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors: 196
12. Tandem autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma - update of the EBMT-NMAM2000 study at 96 months median follow-up: 197
13. Higher probability of survival in complete remission following tandem autologous/reduced-intensity allogeneic transplantation compared to autologous transplantation alone in the NMAM2000 multiple myeloma trial as estimated by multistate models: O158
14. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis
15. Allogeneic stem cell transplantation in patients with systemic AL amyloidosis: a non-interventional study by the MM subcommittee of the Chronic Leukaemia Working Party of the EBMT: 245
16. Treatment of light chain amyloidosis using a combination of lenalidomide and dexamethasone failing melphalan containing chemotherapy: V316
17. Shift to an alternative donor does not improve the outcome after second allogeneic stem cell transplantation (alloSCT) in acute leukaemia relapsing after a first alloSCT - a risk factor analysis by the German Stem Cell Registry (DRST): V545
18. High dose melphalan and autologous stem cell support after VAD chemotherapy for treatment of systemic light chain (AL) amyloidosis: 350
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.